Benjamin Edward Kang

Title: Innovations by Benjamin Edward Kang in Epigenetic Therapy

Introduction

Benjamin Edward Kang is an accomplished inventor based in Baltimore, MD (US). He has made significant contributions to the field of epigenetic therapy, particularly in addressing inherited aortic aneurysm conditions. His innovative approach focuses on the role of transforming growth factor β (TGFβ) in the pathogenesis of aortic aneurysm syndromes.

Latest Patents

Kang holds a patent for a targeted epigenetic therapy aimed at treating inherited aortic aneurysm conditions. The patent details compositions that inhibit histone acetyltransferase activity, which normalizes gene expression in the aorta, preserves aortic wall architecture, and abrogates aneurysm progression. The methods outlined in the patent include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGFβ genes. He has 1 patent to his name.

Career Highlights

Kang is affiliated with Johns Hopkins University, where he continues to advance research in the field of genetics and epigenetics. His work has garnered attention for its potential to transform treatment options for patients suffering from aortic aneurysm syndromes.

Collaborations

Kang collaborates with notable professionals in his field, including Harry C Dietz, who is also recognized for his contributions to genetic research. Their partnership enhances the impact of their work and fosters innovation in therapeutic approaches.

Conclusion

Benjamin Edward Kang's innovative work in epigenetic therapy represents a significant advancement in the treatment of inherited aortic aneurysm conditions. His contributions to the field are paving the way for new therapeutic strategies that could improve patient outcomes.